Skip to end of metadata
Go to start of metadata


CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) Study

CEASAR (Comparative Effectiveness Analyses of Surgery and Radiation in localized prostate cancer) Study


Go to HOME page 

JOURNAL ARTICLES BY YEAR OF PUBLICATION


1996

1. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, Carroll PR. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. [Research Support, Non-U.S. Gov't]. Urology. 1996;48(5):773-777. PMID: 8911524

 

1997

2. Lubeck DP, Litwin MS, Henning JM and Carroll PR. Measurement of health-related quality of life in men with prostate cancer: Data from the CaPSURE database. Qual Life Res. 1997;6(5):385-392. PMID: 9290305   
 

1998

3. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schoenfeld W, Warolin K, Carroll PR. Use of second treatment following definitive treatment for prostate cancer: Data from the CaPSURE database. J Urol. 1998;160(4):1398-1404. PMID: 9751363

4. Kindrick AV, Grossfeld GD, Stier DM, Flanders SC, Henning JM, Carroll PR. Use of imaging tests for staging newly diagnosed prostate cancer: Trends from the CaPSURE database. J Urol. 1998;160(6):2102-2106. PMID: 9817332

5. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessment of health-related quality of life in men with prostate cancer: Results from the CaPSURE database.J Urol. 1998;159(6):1988-1992. PMID: 9598504

6. Penson DF, Litwin MS, Lubeck DP, Flanders SC, Pasta DJ, Carroll PR. Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer. Prostate Cancer Prostatic Dis. 1998;1(3):134-143. PMID: 12496906

 

1999

7. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology.1999;Sep;54(3):503-508. PMID: 10475362

8. Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in health-related quality of life in the first year after treatment for prostate cancer: Results from CaPSURE.Urology.1999 Jan;53(1):180-186. PMID: 9886609

9. Lubeck DP, Pasta DJ, Flanders SC and Henning JM. Approaches to missing data inference:  Results from CaPSURE, an observational study of patients with prostate cancer.Pharmacoeconomics.1999;Feb;15(2):197-204. PMID: 10351192

10. Stier DM, Greenfield S, Lubeck DP, Dukes KA, Flanders SC, Henning JM, Weir J and Kaplan SH. Quantifying comorbidity in a disease-specific cohort: The adaptation of the total illness burden index to prostate cancer. Urology. 1999;Sep;54(3):424-429. PMID: 10475347  

 

2000

11. Grossfeld GD, Chang JJ, Broering JM, Flanders SC, Henning JM, Stier DM Miller DP, Yu J and Carroll PR.  Impact of positive surgical margins on prostate cancer recurrence and secondary cancer treatment:  Data from the CaPSURE Database. J Urol. 2000;Apr;163(4):1171-1177. PMID: 10737489

12. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC and Carroll PR.  Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?  Data from the CaPSURE Database. Urology. 2000;Sep 1;56(3):430-435. PMID: 10962308

Comment Urology. 2001 Feb;57(2):394-5. PMID: 11246646

13. Koppie T, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck DP, Carroll PR, Henning JM, Flanders SC.  Patterns of treatment in patients with prostate cancer initially managed with surveillance: Results from the CaPSURE Database.  J Urol. 2000;164(1):81-88. PMID: 10840429

14. Litwin MS, Pasta DJ, Yu J, Stoddard M, and Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: A longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2000 Dec;164(6):1973-1977. PMID: 11061894

15. Lubeck DP, Litwin MS, Henning JM, Mathias SD, Bloor L and Carroll PR. An instrument to measure patient satisfaction with healthcare in an observational database: Results of a validation study using data from CaPSURE. Am J Manag Care. 2000 Jan;6(1):70-76. PMID: 11009748

 

2001

16. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC and Carroll PR.  Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy:  Results from the cancer of the prostate strategic urologic research database. J Urol. 2001 Mar;165(3):851-856.  PMID: 11176485

17. Litwin MS, Lubeck ML, Stoddard ML, Pasta DJ, Flanders SC and Henning JM. Quality of life before death for men with prostate cancer:  Results from the CaPSURE Database. J Urol. 2001 Mar;165(3):871-875. PMID: 11176489

18. Lubeck DP, Kim H, Grossfeld GD, Ray P, Penson DF, Flanders SC and Carroll PR.  Health related quality of life differences between black and white men with prostate cancer:  Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2001 Dec;166(6):2281-2285. Comment 2291-2. PMID: 11696752

19. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 2001 Aug;58(2 Suppl 1):94-100. Review. PMID: 11502459

20. Moul J, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD and Carroll PR. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001 Oct;166(4):1322-1327. PMID: 11547066

21. Penson D, Stoddard ML, Pasta DJ, Lubeck DP, Flanders SC and Litwin MS.  The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J of Clin Epidemiol. 2001 Apr;54(4):350-358. PMID: 11297885

22. Penson D, Schonfeld WH, Flanders SC, Henke CJ, Stier DM, Warolin KL, Carroll PR and Litwin MS. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis:  Results from the CaPSURE database. Urology. 2001 Mar;57(3):499-503. PMID: 11248628

 

2002

23. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, and Carroll PR.  Contemporary trends in imaging test utilization for prostate cancer staging:  Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2002 Aug;168(2):491-495. PMID: 12131295

24. Grossfeld GD, Latini D, Lubeck DP, Broering JM, Li Y, Mehta SS and Carroll PR. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE. Urology. 2002 Apr;59(4):560-565. PMID: 11927314

25. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS and Carroll PR.  Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol. 2002 Dec;168(6):2510-2515. PMID: 12441951

26. Grossfeld GD, Li Y-P, Lubeck DP, and Carroll PR.  Patterns of failure after primary local therapy for prostate cancer and rationale for second therapy.  Urology. 2002 Sep;60(3 Suppl 1):57-62; discussion 62-3. PMID: 12231051

27. Grossfeld GD, Li Y, Lubeck DP, Broering JM, Mehta SS and Carroll PR. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2002 Aug;168(2): 530-535. PMID: 12131303

28. Litwin ML, Lubeck DP, Spitalny M, Henning JM and Carroll PR. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002 Jul 1;95(1):54-60. PMID: 12115317

29. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, and Carroll PR. Contemporary patterns of androgen deprivation use for newly diagnosed prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2. PMID: 12231037

30. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP and Carroll PR.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol. 2002 Apr;167(4):1653-1658. PMID: 11912382

 

2003

31. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR and Kane CJ.  Sociodemographic and clinical risk characteristics of prostate cancer patients within the Veterans Affairs health care system: Data from CaPSURE. J Urol. 2003 Sep;170(3):905-908. PMID: 12913727

32. Cooperberg MR, Grossfeld GD, Lubeck DP, and Carroll PR.  National practice patterns and time trends in androgen ablation for localized prostate cancer.  J Natl Cancer Inst. 2003 Jul 2;95(13):981-989. This paper has been cited over 100 times since publication. PMID: 12837834 

33. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS and Carroll PR.  How potent is potent?  Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer:  Data from CaPSURE.  Urology. 2003 Jan;61(1):190-196. PMID: 12559294

34. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (Data from CaPSURE). J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7. PMID: 14610406  Erratum in: J Urol. 2004 Feb;171(2 Pt 1):811.

35. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck DP and Chen M-H.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.  J Natl Cancer Instit. 2003 Sep 17;95(18):1376-83. PMID: 13130113

36. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck DP and Chen M-H.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003 Jun 1;21(11):2163-72. PMID: 12775742

37. Downs TM, Grossfeld GD, Sadetsky N, Pasta DJ, Kane CJ, Mehta SS, Carroll PR and Lubeck DP.  Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer:  Data from CaPSURE. J Urol. 2003 Nov;170(5):1822-7. PMID: 14532784

38. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS and Carroll PR.  Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.  J Urol. 2003 Jan;169(1):157-63. PMID: 12478126

39. Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, Carroll RP. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol. 2003 Nov;170(5):1804-7. PMID: 14532780

40. Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS and Carroll PR.  Impact of patient educational level on treatment for patients with prostate cancer: Data from CaPSURE. Urology. 2003 Dec;62(6):1035-9. PMID: 14665350

41. Latini DM, Downs TM, Grossfeld GD, Lubeck DP, Mehta SS and Carroll PR.  Disease recurrence after radical prostatectomy for patients with high-risk disease: Data from CaPSURE and UCSF. Amer J of Urol Rev. 2003;1:62-71. [Request article from jcowan@urology.ucsf.edu]

42. Litwin MS, Lubeck DP, Li Y-P, Henning JM, and Carroll PR.  Health-related quality of life in men with metastatic prostate cancer:  The misleading effect of lead-time bias.  BJU International. 2003 Jan;91(1):9-13. PMID: 12614241

43. Mehta SS, Lubeck DP, Pasta DJ, and Litwin MS.  Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: Results from CaPSURE.  J Urol. 2003 Nov;170(5):1931-3. PMID: 14532810

44. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP and Carroll PR.  Predictors of treatment after initial surveillance in men with prostate cancer: Results from CaPSURE.  J Urol. 2003 Dec;170(6 Pt 1):2279-83. PMID: 14634396 

 

2004

45. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva, SJ, Wallace KL and Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. J Urol. Nov;172(5 Pt 1):1830-4. This paper was featured for CME credits. PMID: 15540732

46. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL and Carroll PR.  Patterns of practice in the United States:  Insights from CaPSURE on prostate cancer management.  Curr Urol Reports. 2004 Jun;5(3):166-72. Review. PMID: 15161564

47. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep;18(10):1239-47; discussion 1248-50, 1256-8. Review. PMID: 15526829

48. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS and Carroll PR.  The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1;22(11):2141-9. This paper has been cited over 100 times since publication. PMID: 15169800

49. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR and the CaPSURE Investigators.  The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry.  J  Urol. 2004 Apr;171(4):1393-401. This paper has been cited over 100 times since publication. PMID: 15017184

50. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck DP and Chen MH.  Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7. PMID: 15535442

51. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K and Carroll PR.  Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE).  J Urol. 2004 Jun;171(6 Pt 1):2255-9. PMID: 15126797

52. Hu JC, Elkin EP, Lubeck DP, Kattan MW, Litwin MS and Carroll PR.  Predicting quality of life after radical prostatectomy: Results from CaPSURE.  J Urol. 2004 Feb;171(2 Pt 1):703-7; discussion 707-8; comment 717-8. PMID: 14713791

53. Litwin MS, Sadetsky N, Pasta DJ and Lubeck DP.  Bowel function and bother after treatment for early stage prostate cancer: A longitudinal quality of life analysis from CaPSURE.  J Urol. 2004 Aug;172(2):515-9. PMID: 15247718

54. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ and Carroll PR.  Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: Data from CaPSURE. J Urol. 2004 Jan;171(1):215-9. PMID: 14665879

55. Speight JL, Elkin EP, Pasta DJ, Silva S, Lubeck DP, Carroll PR, Litwin MS.  Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: Data from CaPSURE.  Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1066-75. PMID: 15519776 

 

2005

56. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ.  The impact of obesity on health related quality of life before and after radical prostatectomy (Data from CaPSURE). J Urol. 2005 Apr;173(4):1132-8. PMID: 15758721

57. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology. 2005 Nov;66(5):1060-5. PMID: 16286124

58. Chan JM, Elkin EP, Silva SJ, Broering JM, Latini DM, Carroll PR. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer.  Urology. 2005 Dec;66(6):1223-8. PMID: 16360447

59. Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE. Cancer Causes Control. 2005 Sep;16(7):789-97. PMID: 16132789

60. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, DuChane J, Carroll PR.  The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.  J Urol. 2005 Jun;173(6):1938-42. Erratum in: J Urol. 2006 Jun;175(6):2369. PMID: 15879786

61. Cooperberg MR, Moul J, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. PMID: 16278465

62. Greene KL, Cowan JE, Cooperberg, MR, Meng MV, DuChane J, Carroll PR, Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov;66(5 Suppl):76-82. PMID: 16194711

63. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR.  Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. J Urol. 2005 Mar;173(3):732-6. This paper was featured for CME credits. PMID: 15711258

64. Langenstroer P, Carroll PR, Thrasher JB. Clinical and pathological characteristics of unstageable prostate cancer: Analysis of the CaPSURE database. J Urol. 2005 Jul;174(1):118-20. PMID: 15947594

65. Meng MV, Elkin EP, Latini DM, DuChane J, Carroll PR.  Treatment of patients with high risk localized prostate cancer: Results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE).  J Urol. 2005 May;173(5):1557-61. PMID: 15821485

66. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.  Ability of two pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. J Urol. 2005 Apr;173(4):1126-31. PMID: 15758720

67. Park S, Meng, MV, Elkin EP, Speight, JL, DuChane J, Carroll PR. Androgen deprivation use with external beam radiation for prostate cancer: Results from CaPSURE. J Urol. 2005 Nov;174(5):1802-7. PMID: 16217291

68. Sadetsky N, Lubeck DP, Latini DM, Pasta DJ, Kawakami J, DuChane J, Carroll PR, CaPSURE Investigators.  Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from CaPSURE. Manag Care Interface. 2005 Feb;18(2):25-30. PMID: 15766061

69. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20;23(27):6556-60. PMID: 16170163

70. Zhou P, Chen M, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1;23(28):6992-8. PMID: 16192586

  

2006

71. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS, Carroll PR. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Urology. 2006 Mar;67(3):559-65. PMID: 16527580

72. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15;107(10):2384-91. PMID: 17039503

73. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.Urology. 2006 Aug;68(2):342-7. PMID: 16904449

74. Greene KL, Elkin EP, Karapetian A, DuChane J, Carroll PR, Kane CJ, and the CaPSURE Investigators. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE. J Urol.  2006 Jan;175(1):125-9; discussion 129. Comment J Urol.  2006 Jan;175(1):16-7.  PMID: 16406887 

75. Hu JC, Elkin EP, Krupski TL, Gore J, Litwin MS. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2006 Jul 15;107(2):281-8. PMID: 16779794

76. Kawakami J, Cowan JE, Elkin EP, Latini DM, Duchane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006 Apr 15;106(8):1708-14. PMID: 16544313

77. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR; CaPSURE Investigators. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol. 2006 Oct;176(4 Pt 1):1382-6. PMID: 16952638

78. Latini DL, Elkin EP, Cooperberg MR, Sadetsky N, DuChane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and Non-Latino White men with localized prostate cancer: Data from CaPSURE. Cancer. 2006 Feb 15;106(4):789-95. PMID: 16400651

79. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, Duchane J, Carroll PR. CaPSURE Investigators. Health-Related Quality of Life for Men with Prostate Cancer and Diabetes: A Longitudinal Analysis from CaPSURE. Urology. 2006 Dec;68(6):1242-7. PMID: 17141841

80. Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll, PR. Comorbidity and Primary Treatment for Localized Prostate Cancer: Data From CaPSURE. J Urol. 2006 Apr;175(4):1326-31. PMID: 16515991

81. Meng MV, Elkin EP, Duchane J, Carroll PR. Impact of increased number of biopsies on the nature of prostate cancer identified. J Urol. 2006 Jul;176(1):63-8; discussion 69. PMID: 16753368

82. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Urol Oncol. 2006 Sep-Oct;24(5):396-402. PMID: 16962488

83. Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006 Dec 1;107(11):2597-603. PMID: 17039498 

 

2007

84. Arredondo SA, Latini DM, Sadetsky N, Kawakami J, Pasta DJ, DuChane J, Carroll PR, CaPSURE Investigators. Quality of Life for Men Receiving a Second Treatment for Prostate Cancer. J Urol. 2007 Jan;177(1):273-8; discussion 278-9. This paper was featured for CME credits. PMID: 17162062

85. Berglund RK, Sadetsky N, Duchane J, Carroll PR, Klein EA. Limited Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Does Not Affect 5-Year Failure Rates for Low, Intermediate and High Risk Prostate Cancer: Results From CaPSURE. J Urol. 2007 Feb;177(2):526-29; discussion 529-30. PMID: 17222625

86. Boorjian S, Cowan JE, Konety B, DuChane J, Tewari A, Carroll PR, Kane CJ. Bladder Cancer Incidence and Risk Factors in Men With Prostate Cancer: Results From Cancer of the Prostate Strategic Urologic Research Endeavor.  J Urol. 2007 Mar;177(3):883-7; discussion 887-8. PMID: 17296367

87. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. J Urol. 2007 Sep;178(3 Pt 2):S14-9. PMID: 17644125

88. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR, CaPSURE Investigators. Incidence of Urethral Stricture After Primary Treatment for Prostate Cancer: Data From CaPSURE. J Urol. 2007 Aug;178(2):529-34; discussion 534. PMID: 17570425 

89. Knight SJ, Latini DM, Hart SL, Sadetsky N, Kane CJ, Duchane J, Carroll PR. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer. 2007 May 1;109(9):1769-76. PMID: 17380491

90. Konety BR, Sadetsky N, Carroll PR. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database. J Urol. 2007 Apr;177(4):1423-5; discussion 1425-6. PMID: 17382745

91. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, DuChane J, Carroll PR and the CaPSURE Investigators. The Relationship between Anxiety and Time to Treatment for Prostate Cancer Patients on Surveillance. J Urol. 2007 Sep;178(3 Pt 1):826-31; discussion 831-2. PMID: 17632144

92. Lee WR, Sharkey J, Cowan JE, Duchane J, Carroll PR, CaPSURE Investigators. Prostate brachytherapy: A descriptive analysis from CaPSURE. Brachytherapy. 2007 Apr-Jun;6(2):123-8. PMID: 17434105

93. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH.  Assessment of prognosis with Total Illness Burden Index for Prostate Cancer (TIBI-CaP): Aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777-83. PMID: 17354226

94. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.Urology. 2007 Jul;70(1):106-10. PMID: 17656218

95. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007 Jul 1;110(1):81-6. PMID: 17516446

96. Scales CD Jr, Moul JW, Curtis LH, Elkin EP, Hughes ME, Carroll PR; CaPSURE Investigators. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007 Dec;70(6):1162-7. PMID: 18158039

97. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality. J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24.

Comment J Natl Cancer Inst. 2007 Oct 17;99(20):1498-9. PMID: 17925537

98. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, Duchane J, Mody RR, Carroll PR. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007 Feb 1;109(3):518-27. PMID: 17186528  
 

2008

99. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008 Jan 15;112(2):307-14. Comment:225-7. PMID: 18050294

100. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol. 2008 May;179(5 Suppl):S14-8. PMID: 18405740

101. Barocas DA, Cowan, JE, Smith JA Jr, Carroll PR; CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. PMID: 18707731

102. Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. Fear of Recurence, Symptom Burden, and Health-Related Quality of Life in Men with Prostate Cancer. Urology. 2008 Dec;72(6):1269-73. PMID: 18342930

103. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A Model That Predicts the Probability of Positive Imaging in Patients With Biochemical Failure After Initial Definitive Local Therapy. J Urol. 2008 Mar;179(3):906-10; discussion 910. PMID: 18207194

104. Cooperberg MR, Cowan J, Broering J, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun;26(3):211-8. PMID: 18369637

105. Davies BJ, Walsh TJ, Ross PL, Knight SL, Sadetsky N, Carroll PR, Kane CJ. Effect of BMI on primary treatment of prostate cancer. Urology. 2008 Aug;72(2):406-11. PMID: 18267336

106. Hart SL, Latini DM, Cowan JE, Carroll PR, CaPSURE Investigators. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer. 2008 Feb;16(2):161-169. PMID: 17638026

107. Hong YM, Hu JC, Paciorek AT, Knight SJ, Carroll PR. Impact of radical prostatectomy positive margins on fear of cancer recurrence: Results from CaPSURE. Urol Oncol. 2010 May-Jun;28(3):268-73. 2008 Oct 9 Epub ahead of print. PMID: 18848785

108. Konety BR, Cowan JE, Carroll PR, CaPSURE Investigators. Patterns of Primary and Secondary Therapy for Prostate Cancer in Elderly Men: Analysis of Data from CaPSURE. J Urol. 2008 May;179(5):1797-803; discussion 1803. PMID: 18343440

109. Lee IH, Sadetsky N, Carroll PR, Sandler HM. The Impact of Treatment Choice for Localized Prostate Cancer on Response to Phosphodiesterase Inhibitors. J Urol. 2008 Mar;179(3):1072-6; discussion 1076. PMID: 18206926

110. Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol. 2008 May-Jun;26(3):271-5. PMID: 18452818

111. Sadetsky N, Lubeck DP, Pasta DJ, Latini DM, DuChane J, Carroll PR. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU Int. 2008 Mar;101(6):691-7. PMID: 18291018

112. Sadetsky N, Elkin EP, Latini DM, Duchane J, Carroll PR, CaPSURE Investigators. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.Prostate Cancer Prostatic Dis. 2008;11(3):280-7. PMID: 17893700

113. Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV; CaPSURE Investigators. Prostate Biopsy Patterns in the CaPSURE Database: Evolution With Time and Impact on Outcome After Prostatectomy. J Urol. 2008 Jan;179(1):136-40. PMID: 17997437

114. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll PR, Litwin MS. Pre-treatment Predictors of Death From Other Causes in Men With Prostate Cancer. J Urol. 2008 Dec;180(6):2447-51; discussion 2451-2. PMID: 18930498

115. van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS. Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res. 2008 Aug;17(6):845-55. PMID: 18506598

116. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS. Quality of Life Among Men with Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database. J Urol. 2008 Dec;180(6):2409-13; discussion 2414. PMID: 18930270

117. Wright JL, Lin DW, Cowan JE, Carroll PR, Litwin MS. Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11(1):67-73. PMID: 17519925

118. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health Related Quality of Life in Patients Treated with Multimodal Therapy for Prostate Cancer. J Urol. 2008 Dec;180(6):2415-22; discussion 2422. PMID: 18930279  
  

2009

119. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer.2009 115(19):4470-6. PMID: 19637339

120. Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):36-9. PMID: 19233568

121. Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. PMID: 19509351

122. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol.2009 Sep 10;27(26):4306-13. PMID: 19667269

123. Dall'Era MA, Hosang N, Konety B, Cowan, JE, Carroll PR. Sociodemographic Predictors of Prostate Cancer Risk Category at Diagnosis: Unique Patterns of Significant and Insignificant Disease.J Urol. 2009 Apr;181(4):1622-7; discussion 1627. PMID: 19230923

124. Davies BJ, Smaldone MC, Sadetsky N, Dall'Era M, Carroll PR. The Impact of Obesity on Overall and Cancer Specific Survival in Men With Prostate Cancer. J Urol. 2009 Jul;182(1):112-7; discussion 117. PMID: 19447437

125. Sadetsky N, Hubbard A, Carroll PR, Satariano W. Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) database. Qual Life Res. 2009;18(8):1019-27. PMID: 19697155

126. Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol. 2009 Nov;182(5):2296-302. PMID: 19758610

 

2010

127. Aaronson DS, Cowan JE, Carroll PR, Konety B. Association of age and response to androgen deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. BJU Int.2010 Apr;105(7):951-5. Epub 2009 Nov 4. PMID: 19889066 

128. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1117-23. PMID: 20124165

129. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR, Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226-34. PMID: 20690197

130. Huang GJ, Sadetsky, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol. 2010 Jun;183(6):2206-12. PMID: 20399462

131. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010 106(5):627-32. Epub 2010 Feb 11 PMID: 20151961 

132. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. Changes in specific domains of sexual function and sexual bother after radical prostatectomy.BJU Int. 2010 Oct;106(7):1022-0. Epub 2010 Feb 23. PMID: 20184571

133. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE. J Clin Oncol. 2010 28(6):1069-74. PMID: 20100957 

134. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol.2010 Jul;184(1):114-9. PMID: 20478578

135. Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010 Mar;91(3):712-21. PMID: 20042525

136. Smaldone MC, Cowan JE, Carroll PR, Davies BJ. Eligibility for Active Surveillance and Pathologic Outcomes in Men Undergoing Radical Prostatectomy in a Large, Community Based Cohort. J Urol. 2010 Jan;183(1):138-43. PMID: 19913808 

137. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara Uro-oncological Research Group (NUORG): a comparison between the CaPSURE Data and the NUORG Data. Jpn J Clin Oncol. 2010 Jun;40(6):588-92. PMID: 20299498

 

2011

138. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21;306(11):1205-14. PMID: 21934053

139. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10;29(2):235-41. Epub 2010 Dec 6. PMID: 21135285

140. Chamie K, Sadetsky N, Litwin MS. Physician assessment of pretreatment functional status: a process-outcomes link. J Urol. 2011 Apr;185(4):1229-33. PMID: 21334026

141. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039-46. PMID: 21647869

142. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011;29(3):265-71. PMID: 21347810

143. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10;29(26):3510-6. PMID: 21844498

144. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?BJU Int. 2012;109(10):1520-4. Epub 2011 Oct 14. PMID: 21999368

145. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15;117(2):283-9. Epub 2010 Nov 22. PMID: 21210472

146. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. J Urol. 2011;186(6):2228-32. PMID: 22014796

147. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res. 2011;71(11):1-7. PMID: 21610110

148. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011;117(19):4406-13. PMID: 21412760

 

2012

149. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth joint meeting of J-CaP and CaPSURE: Advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar;42(3):226-36. PMID: 22217576

150. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 1;30(28):3540-4. PMID: 22927523

151. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer conundum revisited: Treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955-63. PMID: 22605665

152. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012;15(4):374-9. PMID: 22710832

153. Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2012 Jul 1; 131(1):201-10. Epub 2011 Aug 30. PMID: 21823116

154. Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto KI, Nishimura K. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Urol Int. 2012;89(1):45-51. PMID: 22441013

155. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1;18(19):5471-8. PMID: 23008476

 

2013

156. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll PR. Sixth Joint Meeting of J-CaP and CaPSURE: a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul;43(7):756-66. PMID: 23723314

157. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul;2(4):445-60. PMID: 24236685

158. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2013 Dec;73(16):1786-95. PMID: 24038157

159. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL. Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era. Urology. 2013 Jul;82(1):60-6. PMID: 23706257

160. Harris CR, Punnen S, Carroll PR. Men with low preoperative sexual function may benefit from nerve-sparing radical prostatectomy. J Urol. 2013 Sep;190(3):981-6. PMID: 23410984

161. Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int. 2013;111(2):213-20. Epub 2012 Aug 29. PMID: 22928860

162. Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of quality of life in patients with prostate cancer and their doctors. Urol. 2013 Jan;189(1 Suppl):S59-65. PMID: 23234635

 

2014

163. Brajtbord JS, Punnen S, Cowan JE, Welty CJ, Carroll PR. Age and baseline Quality of Life at Radical Prostatectomy: Who Has the Most to Lose? J Urol. 2014 Aug;192(2):396-401. PMID: 24582539

164. Broering JM, Paciorek A, Carroll PR, Wilson LS, Litwin MS, Miaskowski C. Measurement equivalence using a mixed-mode approach to administer health-related quality of life instruments. Qual Life Res2014 Mar;23(2):495-508. Epub Aug 13 2013.  PMID: 23943258

165. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation on mental and emotional well-being in men with prostate cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. JUrol2014 Apr;191(4):964-70. Epub Oct 29 2013. PMID: 24184370             Reply to letter to the editor PMID: 25194545 

166. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014 Feb 15;120(4):507-12. Epub 2013 Oct 25. PMID: 24496867

167. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014 Apr;25(4):515-23. PMID: 24504435

168. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):174-9. PMID: 24614692

169. Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM. Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSURE. J Urol2014 Apr;191(4):971-6. Epub Oct 3 2013. PMID: 24095905

170. Ten Ham RM, Wilson LS, Broering JM, Cooperberg MR, Carroll PR. Sustainable measurement of response shift in prostate cancer patients: adjusting health related quality of life with the Then-test. Value Health. 2014 Nov;17(7):A651. PMID: 27202352

171. Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines in brachytherapy monotherapy practice patterns for prostate cancer. Cancer2014 Mar 15;120(6):824-32. Epub Dec 2 2013.  PMID: 24301555

172. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15;20(20):5302-10. PMID: 25320374


2015

173. Cooperberg MR, Carroll PR. Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7;314(1):80-2. PMID: 26151271

             Reply to letter to the editor PMID: 26547474

174. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carrol PR, Hernan MA. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An Observation follow-up study. Eur J Cancer. 2015 May;51(7):817-24. PMID: 25794605

175. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 2015 Sep;68(3):480-6. PMID: 25656807

176. Hsu CC, Paciorek AT, Cooperberg MR, Roach M 3rd, Hsu IC, Carroll PR. Post-operative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov;116(5):713-20. PMID: 25600860

177. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. Current use of imaging after primary treatment of prostate cancer. J Urol. 2015 Jul;194(1):98-104. PMID: 25640648

178. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015 Mar;67(3):451-7. Epub 2014 Apr 5. PMID: 24746973

179. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: Results from the CaPSURE Registry. Eur Urol. 2015 Oct;68(4):600-8. Epub 2014 Sep 18. PMID: 25242555


2016

180. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016 Jan;117(1):102-9. Epub 2015 May 14. PMID: 25238114


2017

181. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 May;71(5):750-759. Epub 2016 Dec 8. PMID: 27940155 

182. Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll PR, Cooperberg MR. Interpreting patient-reported urinary and sexual function outcomes across multiple validated instruments. J Urol. 2017 Mar 22. Epub ahead of print  PMID: 28342935

183. Herlemann A, Cowan JE,Carroll PR, Cooperberg MR. Community-Based Outcomes of Open versus Robot-Assisted Radical Prostatectomy. Eur Urol. 2017 May 9. PMID: 28499617

 

In press

 

CEASAR papers

Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCullum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Phillips S, Stroup AM, Wu XC, Penson DF. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017 Mar 21;317(11);1126-40. PMID: 28324093

Barocas DA, Chen VW, Cooperberg MR, Goodman M, Graff JJ, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup AM, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul;2(4);445–60. PMID: 24236685

Friedly JL, Bauer Z, Comstock BA, DiMango E, Ferrara A, Huang SS, Israel E, Jarvik JG, Nierenberg AA, Ong MK, Penson DF, Smith-Bindman R, Stillman AE, Vollmer WM, Warren SM, Zhan C, Hsia DC, Trontell A.Challenges conducting comparative effectiveness research: the Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE). Comparative Effectiveness Research. 2014;4;1-12. PMID: None DOI: http://dx.doi.org/10.2147/CER.S59136

O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF. The comparative harms of open and robotic prostatectomy in population based samples. J Urol. 2016 Feb;195(2):321-9. PMID: 26343985

Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014 Apr 15;120(8):1263-71. PMID: 24510400

Resnick MJ, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MC, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Standord JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the last two decades: Implications for Comparative Effectiveness Research. Eur Urol. 2015;67(6):1019-25. PMID: 25174325  DOI:  http://dx.doi.org/10.1016/j.eururo.2014.08.035

Sohn W, Resnick MJ, Greenfield S, Kaplan SH, Phillips S, Koyama T, Goodman M, Hamilton AS, Hashibe M, Hoffman KE, Paddock LE, Stroup AM, Wu XC, Penson DF, Barocas DA. Impact of adherence to quality measures for localized prostate cancer on patient-reported health-related quality of life outcomes, patient satisfaction, and treatment-related complications. Med Care. 2016 Aug;54(8):738-44. PMID: 27219634


Related papers

Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May;105(10):1477-22. Review. PMID: 20346051  

Moul JW, Kibel AS, Roach M 3rd, Dreicer R. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov;78(5 Suppl):S478-81. PMID: 22054918

Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov;184(5):1931-6. PMID: 20846693

Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Do Nomograms Designed to Predict Biochemical Recurrence (BCR) Do a Better Job of Predicting More Clinically Relevant Prostate Cancer Outcomes than BCR? A Report from the SEARCH Database Group. PMID: 23806388


Go to HOME page